business

FABENTECH is the only French SME chosen to be a part of the COUNTERACT European consortium, which aims to develop medical countermeasures targeting Chemical, Biological, Radiological and Nuclear (CBRN) threats Funded by the European Defence Fund and coordinated by the French Alternative Energies and Atomic Energy Commission (CEA), the consortium includes 26 partners from 11 …

Fabentech’s polyclonal antibody technology chosen by the European Commission to counter CBRN threats within the framework of the Counteract consortium Read More »

Fab’entech, a French biotech specialised in the development and production of polyclonal antibodies, presents its new industrial site located in Saint-Priest, to the south-east of Lyon. The 1,000 m2 production site is now operational and will give Fab’entech the capacity to manufacture all of its innovations (biodefense and anti-COVID-19 programme: FabenCOV®) in France. Close-up of this new site, a key asset in the development of the biotech’s activities.

Sébastien Iva is the new Chief Executive Officer of Fab’entech, a Lyon-based biotech created in 2009 and specialised in the development and production of polyclonal antibodies intended for the treatment of emerging infectious diseases and the development of biodefense solutions. His mission is to ensure its development and transformation, with the stated objective of becoming a key player in the field of polyclonal antibodies. He took over from Bertrand Lépine, founder of Fab’entech, who now becomes a member of the Supervisory Council.